Work Here?
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$125M
Headquarters
San Diego, California
Founded
2018
Overview
Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.
Simplify's Take
What believers are saying
- FDA cleared INDs for TRX103 in GvHD and TRX319 in MS, trials advancing with positive safety data.
- Secured $75M Series A from Column Group and $50M financing plus $8M CIRM grant.
- San Diego biotech hub provides talent access near UCSD and 400+ local companies.
What critics are saying
- Manufacturing scale-up fails, halting TRX103 and TRX319 GMP production within 12-24 months.
- TRX319 Phase 1 triggers cytokine release safety signal, terminating MS program in 6-18 months.
- Regeneron and AstraZeneca displace Tr1X with faster Treg efficacy readouts in 18-36 months.
What makes Tr1X unique
- Tr1X engineers allogeneic Tr1 Treg cells mimicking natural Tr1 cells for superior inflammation homing.
- Proprietary platform enables scalable off-the-shelf CAR-Treg therapies like TRX319 for progressive MS.
- Founded on Dr. Maria Grazia Roncarolo's Tr1 cell discovery, first in clinical trials.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$125M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
401(k) Company Match
Flexible Work Hours
Stock Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↑ 4%Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.
Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...
TR1X awarded $8M grant for TRX103 GvHD trial.
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025
Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.
Tr1X is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Tr1X
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Early VC
Total Funding
$125M
Headquarters
San Diego, California
Founded
2018
Tr1X is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today